Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma.
暂无分享,去创建一个
G. Salles | S. Montoto | H. Holte | M. Federico | A. Guarini | E. Zucca | L. Marcheselli | I. Aurer | F. Morschhauser | M. Alcoceba | M. Gomes da Silva | S. Galimberti | C. Sarkozy | L. Magnano | M. Chamuleau | M. Manni | M. Wondergem | S. Alonso-Álvarez | S. Lockmer | Y. Stepanishyna | M. D. Caballero Barrigón
[1] N. Nagy,et al. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma , 2020, Genes.
[2] S. Barrington,et al. Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study , 2020 .
[3] M. Calaminici,et al. IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution. , 2020, Blood.
[4] D. Scott,et al. Early progression after BR is associated with high risk of transformation in advanced stage follicular lymphoma. , 2019, Blood.
[5] A. López-Guillermo,et al. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population , 2019, British journal of haematology.
[6] D. Rossi,et al. Liquid biopsy in lymphoma , 2019, Haematologica.
[7] Ash A. Alizadeh,et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] E. Kimby,et al. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. , 2018, The Lancet. Haematology.
[9] E. González-Barca,et al. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome , 2017, Hematological oncology.
[10] R. Foà,et al. Diffuse large B-cell lymphoma genotyping on the liquid biopsy. , 2017, Blood.
[11] A Rosenwald,et al. Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma , 2016, Leukemia.
[12] L. Staudt,et al. Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. , 2016, Blood.
[13] E. Feuer,et al. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[14] J. Friedberg,et al. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). , 2015, Blood.
[15] J. Cerhan,et al. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[17] Ash A. Alizadeh,et al. Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. , 2015, Blood.
[18] L. Staudt,et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. , 2015, The Lancet. Oncology.
[19] H. Feilotter,et al. Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome , 2014, Clinical Cancer Research.
[20] Raul Rabadan,et al. Genetics of follicular lymphoma transformation. , 2014, Cell reports.
[21] M. Calaminici,et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma , 2013, Nature Genetics.
[22] J. Cerhan,et al. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Federico,et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] O. Elemento,et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.
[25] I. Lossos,et al. Transformation of follicular lymphoma. , 2011, Best practice & research. Clinical haematology.
[26] M. Calaminici,et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.